[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"womens-health\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:womens-health":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,62,95,124,158,193,225,252,277,302],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100509219","improving-alcohol-and-substance-use-care-access-outcome-equity-during-the-reproductive-years-100509219",false,"NCT05910580","Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years","Improving Alcohol and Substance Use Care Access, Outcomes, and Equity During the Reproductive Years: A Type 1 Hybrid Trial in Family Planning Clinics","Inclusion Criteria:\n\n* Over the age of 18 years\n* U.S. residing\n* Have internet access (own a computer or smart phone)\n* Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments\n\nExclusion Criteria:\n\n* Not capable of communicating (reading, speaking, writing) in English or Spanish","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic.\n\nThe main questions it aims to answer are:\n\n* Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing?\n* Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity?\n* Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)?\n\nParticipants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months.\n\nResearchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.",[26,27,28,29,30,31,32,33,34,35],"Alcohol-Related Disorders","Substance-Related Disorders","Mental Health","Reproductive Health","Sexual Health","Sexually Transmitted Diseases","Contraception","Maternal Health","Pregnancy","Women's Health",[37,38,39,40,41,42,43,44,45,46,47,48],"Implementation Science","Mass Screening","Motivational Interviewing","Referral and Consultation","Quality of Health Care","Early Medical Intervention","Family Planning Services","Primary Health Care","Reproductive Health Services","Telemedicine","Preconception Care","Young Adult","RECRUITING","2026-06-12",{"date":52,"type":53},"2026-06-15","ACTUAL",{"date":55,"type":53},"2025-07-03",{"date":57,"type":20},"2027-05-31",{"name":59,"class":60},"Emory University","OTHER",4,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100633290","female-reproductive-health-in-canadian-armed-forces-100633290","NCT07524764","Female Reproductive Health in Canadian Armed Forces","Female Reproductive Health in Canadian Armed Forces: Experience, Access to Care, and Support","BEARH2025","Inclusion Criteria (part 1):\n\n* Female (biological sex)\n* Aged at least 18 years old\n* Completed Basic Military Qualification (including Regular Forces, Reserve Forces (Class A, B, or C), Canadian Rangers, COATS instructors, and survivors of the LGBT Purge whose official records of service have been changed to reflect the nature of their discharge)\n\nInclusion Criteria (part 2):\n\n* Female (biological sex)\n* Aged at least 18 years old\n* Completed Basic Military Qualification (including Regular Forces, Reserve Forces (Class A, B, or C), Canadian Rangers, COATS instructors, and survivors of the LGBT Purge whose official records of service have been changed to reflect the nature of their discharge)\n* Have experienced a reproductive health issue while serving in the CAF\n\nInclusion Criteria (part 3):\n\n* Healthcare providers (CAF Health Services, public servant, civilian) who has treated female patients who are actively serving and\u002For Veterans of the CAF in the past 5 years.\n* Stakeholders who are involved in supporting reproductive health of female members of the CAF and\u002For Veterans.\n* Policymakers who are involved in supporting reproductive health of female members of the CAF and\u002For Veterans.",true,"FEMALE",{"count":73,"type":20},1121,"OBSERVATIONAL","This is a mixed-method study aimed at gathering new evidence on reproductive health among female service members in the Canadian Armed Forces (CAF). Reproductive health includes four primary domains: contraception; undesired reproductive outcomes (including unintended pregnancy, adverse pregnancy outcomes, and infertility); assisted reproductive care; and pelvic floor dysfunctions. Additional factors that may influence reproductive outcomes will also be explored, including gynecological health (including but not limited to menstrual health, menopause, breast injury, sexually transmitted and blood-borne infections) as well as physical and psychological health (including but not limited to repetitive strain injuries, depression, and post-traumatic stress disorder). Evidence gathered on reproductive health issues will include, but not limited to, the lived experiences (occurrence), associated risk factors, access to care, including barriers and facilitators, service utilization, and career-related impacts among actively serving members and Veterans of the CAF. These will inform the development of recommendations and support services aimed at improving reproductive health care within the CAF. This project is divided into 3 convergent parts:\n\nPart 1: An online pan-Canadian survey that will achieve a minimum total sample of 1067 participants.\n\nPart 2: Semi-structured individual interviews (open-ended questions) will be conducted with female CAF members and Veterans who have experienced at least one reproductive health issues. A total of 30 participants are estimated to be required to achieve data saturation across the four primary domains.\n\nPart 3: Semi-structured group discussion (open-ended questions) will be conducted with healthcare providers, who have experience with treating female reproductive health issues in CAF members, as well as stakeholders and policymakers involved in supporting female members of the CAF\u002FVeterans. A total of 24 healthcare providers\u002Fstakeholders\u002Fpolicymakers will form 3 group discussion (8 participants\u002Fgroup).\n\nFor all 3 parts, efforts in recruitment will be made to ensure representation across CAF elements, minority groups, and native language (French and English).",[34,77,78,32,79,35],"Pelvic Floor Dysfunction","Military Personnel","Infertility",[81,82,34,79,83,32,84,85],"Reproductive health issue","Women's health","Pelvic floor dysfunction","Canadian Armed Forces","Military personnel","2026-05-19",{"date":88,"type":53},"2026-05-22",{"date":86,"type":53},{"date":91,"type":20},"2026-12-15",{"name":93,"class":60},"Université de Sherbrooke",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":71,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":94},"100532403","therapeutic-educational-physiotherapy-on-pain-physical-functionality-and-quality-of-life-in-women-with-endometriosis-100532403","NCT06212349","Therapeutic-educational Physiotherapy on Pain, Physical-functionality and Quality of Life in Women With Endometriosis.","Effect of a Therapeutic-educational Physiotherapy Program on Pain and the Physical-functional Sphere in Women With Endometriosis and Its Impact on Quality of Life","PHYSIO_ENDOM","Inclusion Criteria:\n\n* Diagnosis of endometriosis made by imaging techniques (MRI or ultrasound) or by surgery.\n* A period of 3 months or more since the last surgery if they have undergone surgery.\n* Who are receiving hormone treatment and have their disease under control.\n* Persistent pelvic pain for at least 3 months.\n* With pain and hypertonus in the pelvic musculature, myofascial syndrome, vestibulodynia or pudendal neuropathy.\n* Consent to participate in the study\n* Capable of carrying out the follow-up of the study until the final visit.\n* Who have audiovisual resources and the internet at their disposal.\n\nExclusion Criteria:\n\n* Women in the menopausal phase\n* Women undergoing fertility treatment or planning to undergo fertility treatment in the next 3 months.\n* Pregnant women.\n* Women undergoing physiotherapy treatment or who have undergone physiotherapy treatment in the last 3 months.\n* Having suffered a fracture in the last 3 months in the lower limb that limits their functional capacity.\n* Cognitive illness that prevents correct comprehension of the exercises.\n* Musculoskeletal pathology or neuropathy in acute phase.\n* Having suffered or suffering from a neoplastic disease.\n* Untreated endometriosis\n* Acquired genital abnormalities of the pelvis or pelvic floor.\n* Women in a situation of litigation or economic compensation, or pending the granting of a degree of disability.\n* Severe mental illness (schizophrenia, borderline personality disorder, etc.)","45 Years",{"count":105,"type":20},62,[23],"This is a randomized clinical trial that will be carried out in women with endometriosis divided into two groups: the experimental group (EG) that will receive therapeutic-educational physiotherapy, which will combine therapeutic exercise with a pain education program, and the control group (CG) who will receive the pain education program.\n\nThe participants will be evaluated at three moments: before starting the study (T1), after the 8-week treatment program (T2) and after another 8 weeks of follow-up in which they will be encouraged to continue with the treatment (T3). The initial assessment will include a medical and physiotherapy history, and at T1, T2 and T3 the following will be assessed: pain, abdominopelvic mobility, muscle status, functionality, sexual function, quality of life, stress and biomarkers of chronic inflammation.",[109,110,35],"Endometriosis","Chronic Pain",[112,110,113,114,115],"endometriosis","Physical Therapy","Health education","Women","2026-05-15",{"date":86,"type":53},{"date":119,"type":53},"2024-09-09",{"date":121,"type":20},"2027-12-22",{"name":123,"class":60},"University of Valencia",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":70,"sex":71,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":157},"100633252","effera-dose-response-womens-health-100633252","NCT07524270","Effera Dose Response: Women's Health","Dose-Response of Effera® Supplementation for Women's Health Outcomes","Inclusion Criteria:\n\nParticipants must meet all of the following criteria to be eligible for participation:\n\n* Women, 18 - 40 years of age\n* No changes in hormonal contraception use in the past 6 months\n* Regular or mildly irregular cycles (24-45 days) for the past 3 months\n* In the majority (\\>3) of menstrual cycles over the past 6 months, experience menstrual cramps on a pain scale of at least 4 out of 10 (1=no pain at all and 10 = worst pain ever experienced)\n* In the majority (\\>3) of menstrual cycles over the past 6 months, experience pain so significant that it requires over-the-counter pain medication for at least 2 days (on average) per period\n* In the majority (\\>3) of menstrual cycles over the past 6 months, experience at least one day per cycle where menstrual symptoms either interfere with work or school performance, limit normal daily activities or exercise, or lead to staying home, leaving early, or modifying plans\n* Reports noticeable mood or physical changes in the 5-7 days before menses in most cycles (irritability, mood, bloating, breast tenderness, cravings, sleep changes, etc.)\n* Generally healthy and free of diseases or disorders that impact functioning of the gastrointestinal system.\n* No recent or acute infection in the past 30 days and no chronic systemic illness\n* No psychiatric condition that, in the investigator's judgment, would impair consent capacity, protocol adherence, or valid completion of questionnaires.\n* If psychiatric medication is used: stable regimen for ≥3 months with no anticipated changes during the study\n* Body mass index (BMI) 18.5 to 32.5 kg\u002Fm2 (Inclusive)\n* Non-smoker\n* Agrees to not use any new vitamin, mineral, or dietary supplement product until after study completion and to not take any vitamins, minerals or dietary supplements 24 hours prior to the exercise test visits.\n* Willing and able to maintain consistent diet and physical activity habits\n* Willing and able to provide consent and comply with the protocol\n* Access to a smartphone, electronic, or personal computer with access to the internet to allow for completion of all online instruments and study reporting\n* Able to read and understand English at the 6th-grade level and sign the informed consent to participate in the study\n* Willing to use reliable contraception or maintain sexual abstinence during the study\n\nExclusion Criteria:\n\nParticipants will be excluded if any of the following apply:\n\n* Current or prior diagnosis from a licensed medical provider of Premenstrual Dysphoric Disorder (PMDD) or Premenstrual Syndrome (PMS) requiring ongoing medical or psychiatric treatment.\n* History of any food allergies or intolerances that could impact digestive outcomes and history of irritable bowel syndrome, inflammatory bowel disease (Crohn's, ulcerative colitis, celiac), gastroparesis, chronic constipation or diarrhea requiring medication, or GI surgery\n* Has any of the following medical conditions: bleeding disorders, active heart or cardiovascular disease, uncontrolled high blood pressure (≥ 140\u002F90 mmHg), renal or hepatic impairment\u002Fdisease, Type I or II diabetes, any neurologic disease or disorder that may impact cognition or mood, unstable thyroid disease, chronic inflammatory conditions, immune disorders (such as HIV\u002FAIDS), or any medical condition deemed exclusionary by the Principal Investigator (PI)\n* Acute illness or infection within the past 30 days\n* History of cancer (except localized skin cancer without metastases) within 5 years prior to screening.\n* Recently started taking (within the past 90 days or has had their dosage adjusted in the past 90 days) antihypertensives, hypoglycemic medications, GLP1 agonists of any class or type, stimulatory asthma medications, or any other prescription or over-the-counter medication that confound the outcomes measured in this study\n* Habitual use of anti-inflammatory medications for 30 days prior to providing consent\n* Current or past diagnosis of bipolar I\u002FII disorder, schizophrenia spectrum or other psychotic disorder; psychiatric hospitalization, suicidal ideation, attempt, or self-harm behavior in the past 12 months\n* Initiation, discontinuation, or dose change of any psychotropic medication within the past 3 months, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, stimulants, or sedative-hypnotics\n* Subject has an allergy to any ingredients in the study product\n* Subject has a history of drug or alcohol abuse in the past 12 months\n* Excessive alcohol intake defined as greater than 7 drinks\u002Fweek or binge episodes\n* Any condition or abnormality that in the expert opinion of the PI, participation in the study would compromise the safety of the subject or the quality of the study data.\n* Participating in or has participated in another research study within 30 days prior to the screening visit that could confound outcomes\n* Currently pregnant or lactating\n* Currently in prison, custody, or otherwise considered a ward of the state preventing their ability to free participate","40 Years",{"count":133,"type":20},160,[23],"The goal of this clinical trial is to learn if a human equivalent lactoferrin supplement (effera®) can improve menstrual symptoms, mood, and quality of life in healthy women aged 18-40.\n\nThe main questions it aims to answer are:\n\nDoes effera® reduce the severity of menstrual symptoms?\n\nDoes effera® improve mood, gastrointestinal symptoms, and overall well-being?\n\nResearchers will compare three different doses of effera® to a placebo (a look-alike supplement with no active ingredient) to see if the supplement improves these outcomes.\n\nParticipants will:\n\nTake the assigned supplement (effera® or placebo) daily for 12 weeks\n\nComplete online questionnaires about menstrual symptoms, mood, and health\n\nOptionally share sleep and activity data from a wearable device",[137,138],"Womens Health","Menstrual Symptoms",[140,141,142,143,144,145,146],"Lactoferrin","Menstrual health","Dysmenorrhea","Effera","Gastrointestinal symptoms","Mood","Quality of life","2026-04-06",{"date":149,"type":53},"2026-04-13",{"date":151,"type":20},"2026-04",{"date":153,"type":20},"2026-12",{"name":155,"class":156},"Helaina Inc.","INDUSTRY",2,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":71,"minAge":131,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":182,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":191,"locationsCount":94},"100590048","changes-in-the-impact-of-genitourinary-syndrome-of-menopause-with-a-novel-nonhormonal-vulvovaginal-gel-assessed-by-proms-100590048","NCT06962345","Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.","Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs. Phase 2, Single Arm, Interventional, Longitudinal, Clinical Trial. Part of STOP GSM PROJECT.","STOPGSMP","Inclusion Criteria:\n\n* Patient has to have at least one symptom of GSM or suffer from symptoms related to vulvovaginal atrophy (as evidenced by gynecological examination with a Vaginal Health Index ≤15).\n* Patient must be postmenopausal with at least 1 year without a menstrual period.\n* Patient must consider that her quality of life is affected by GSM symptoms\n* Patient not followed due to any gynecological disease.\n* All participants must be able to understand and to fill in the self-reported questionnaires.\n\nExclusion Criteria:\n\n* Patients that do not want to fill the questionnaire, especially the questions that address sexual functioning.\n* Participants that use any oral products containing hormones or estrogen receptor modulators for the past 8 weeks, nor vaginal topical hormone products within 4 weeks, neither prescription nor non-prescription therapies for GSM, including topical vaginal non-hormonal lubricants or moisturizers for the last week.\n* Patients with history of vulvar, vaginal and\u002For cervical malignancy.\n* Patients having received radiotherapy treatment in the pelvic and\u002For genital region.\n* Patients with any type of disease that causes alteration of collagenogenesis.\n* Patients that use cytotoxic drugs leading to mucositis and alterations of tissue regeneration in the last 6 months.\n* Patients having received laser and\u002For radiofrequency treatment for handling genital atrophy or other pelvic floor dysfunctions.\n* Patients with active urinary and\u002For genital tract infection.\n* Patients with history of malignant neoplasm of the urinary system.\n* Patients with severe stress urinary incontinence (Sandvik test score equal to or greater than 8).\n* Patients with diagnosis of pelvic organ prolapse grade III or higher according to the POP-Q classification.\n* Patients with medical or surgery history that, at the investigator's discretion, does not allow participation in the study.\n* Patients with any other condition that, at the investigator's discretion, implies that the patient is unable to understand the implication of participating in the study and\u002For following the established procedures.","70 Years",{"count":168,"type":20},80,[23],"The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the vulvovaginal area. Symptoms of vaginal atrophy will be compared before and after 8 weeks of use of the tested gel with the Day-to-Day Impact of Vaginal Aging (DIVA) PROMs questionnaire to assess changes impact of GSM symptoms.",[172,173,174,175,176,177,178,179,180,181],"Vulvar Atrophy","Vulvovaginal Signs and Symptoms","Genitourinary Syndrome of Menopause","Quality of Life","Menopause Related Conditions","Dyspareunia","Urinary Incontinence, Urgency-frequency","Sexual Function","Women´s Health","Vaginal Dryness",[174,173,183,175,184,180],"Patient Reported Outcome Measures","Day-to-Day Impact of Vaginal Ageing","2026-03-25",{"date":187,"type":53},"2026-03-30",{"date":189,"type":53},"2024-01-08",{"date":153,"type":20},{"name":192,"class":156},"Mucosa Innovations, S.L.",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":71,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":21,"phases":204,"briefSummary":206,"conditions":207,"keywords":212,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100625933","early-phase-1-effectiveness-of-a-vaginal-gel-on-cin12-regression-and-hpv-clearance-100625933","NCT07429071","Effectiveness of a Vaginal Gel on CIN1\u002F2 Regression and HPV Clearance.","Effectiveness of a Non-Invasive Treatment Using a Vaginal Gel in Promoting HPV Clearance and Regression of Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Positive HPV test\n* Underwent colposcopy with subsequent histopathological findings of CIN1 or CIN2\n* Allocated to a 'watchful waiting' management strategy.\n* Understand Danish, written and orally.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Unexplained bleeding\n* Immunosuppressive\u002Fmodulatory diseases or treatment\n* Cancer or cancer related diseases","30 Years","50 Years",{"count":203,"type":20},70,[205],"EARLY_PHASE1","The goal of this clinical trial is to evaluate whether a Coriolus versicolor-based vaginal gel promotes regression of CIN1\u002FCIN2 and facilitates HPV clearance in women aged 30-50 years diagnosed with CIN1 or CIN2 and HPV. In addition, the study will assess patient satisfaction, treatment compliance and characterize the vaginal microbiome.\n\nThe primary outcomes therefore is:\n\n* the regression of the cervical dysplasia from baseline to the follow-up (6 months), which will be assessed through either liquid-based cytology and\u002For histopathology (biopsy).\n* HPV clearance from baseline to follow-up (6 months)\n\nIn this randomized controlled study, eligible participants will be randomized 1:1 into two groups:\n\n1. Intervention group: Women (n=35) will apply a CV-based vaginal gel (Papilocare®) daily for 21 days for 3 months. Afterward, the gel should be used every other day for an additional 3 months. Every month includes a 7-day break due to menstruation (28 days cycle).\n2. Control group; Women (n=35) will follow the conventional \"wait and see\" approach.",[137,208,209,210,211],"Cervical Dysplasia","Cervical Intraepithelial Neoplasia (CIN)","Non-invasive Treatment","Human Papilloma Virus (HPV)",[137,208,209,213,214],"Human Papillomavirus (HPV)","Non-Invasive Treatments","NOT_YET_RECRUITING","2026-03-02",{"date":218,"type":53},"2026-03-04",{"date":220,"type":20},"2026-03",{"date":222,"type":20},"2026-09",{"name":224,"class":60},"University of Aarhus",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":234,"conditions":235,"keywords":239,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":94},"100590313","study-on-sex-specific-individualized-dose-calculation-of-contrast-agent-in-ct-examinations-100590313","NCT06965790","Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations","Randomized Controlled Study on Sex-specific, Individualized Dose Calculation of Intravenously Administered Contrast Agent in CT Examinations in Portal Venous Phase to Achieve Equivalent Contrast in Men and Women","Inclusion Criteria:\n\n* Presence of a justifying indication for a CT scan of the thorax and abdomen with application of intravenous contrast medium and a start delay corresponding to the portal venous contrast medium phase\n* Ability to give informed consent, as well as written and verbal consent to participate in the study available\n\nExclusion Criteria:\n\n* Cardiorespiratory instability (as assessed by the attending physician)\n* Age \\\u003C18 years\n* Existing or suspected pregnancy\n* Known post hepatectomy and\u002For splenectomy\n* Lack of current height (in the same inpatient\u002Foutpatient hospital stay) or lack of possibility of height measurement\n* Lack of current daily body weight or inability to measure body weight\n* Height under 140 cm or over 220 cm\n* Body weight under 50 kg or over 120 kg\n* Contraindication to iodine-containing contrast medium (Allergy to contrast media containing iodine, Severe renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin), Hyperthyroidism)",{"count":19,"type":20},[23],"A large proportion of radiological CT examinations require the intravenous administration of iodine-containing X-ray contrast medium. According to current guidelines, the amount required for CT examinations in the (portal) venous phase is calculated on the basis of body weight (e.g. 0.2-0.4 g iodine\u002Fkg body weight), but a standardized application dose of the contrast agent is often also used.\n\nIn earlier studies, the investigators found that the iodine contrast in vessels and organs achieved with a standardized amount of contrast agent differs significantly between women and men. On average, women showed around 10% higher iodine contrast than men of the same height and weight. The investigators attribute these differences to physiological, sex-specific differences in blood volume. For example, the blood volume of a woman 175 cm tall and weighing 75 kg is approx. 400 ml less than that of a man of the same height and weight (approx. 4.6 vs. 5.0 l, calculated according to Nadler). Taking blood volume into account, sex was no longer a significant influencing factor in a retrospective cohort (n=274).\n\nThe investigators would now like to investigate these results in a prospective study. For this purpose, two groups of patients with a clinical indication for a contrast-enhanced CT scan in the venous phase will be compared:\n\n1. control group with regular weight-adjusted (n = 200)\n2. study group with dosing according to blood volume (n = 200).\n\nThe hypothesis is that the application scheme adapted to the blood volume leads to a more homogeneous contrasting of women and men. In order to quantify this effect, the iodine contrast values of both groups will be quantitatively analyzed, taking into account other influencing variables (height, weight).\n\nThe investigators hope that this approach will reduce or even eliminate the observed sex-specific differences. This would lead to a sex-equal contrast based on an individualized amount of contrast medium.",[236,237,238,137],"CT Scans","Contrast Media","Gender",[240,236,237,241,242],"CT","contrast","gender","2025-12-07",{"date":245,"type":53},"2025-12-09",{"date":247,"type":53},"2025-04-01",{"date":249,"type":20},"2027-03",{"name":251,"class":60},"University Hospital Augsburg",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":70,"sex":71,"minAge":17,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":267,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":94},"100492831","the-impact-of-the-menstrual-cycle-on-physical-exercise-and-performance-100492831","NCT05697263","The Impact of the Menstrual Cycle on Physical Exercise and Performance","Inclusion Criteria:\n\n* Women exercising at least 3-4 times a week on a high level\n* Regular menstrual cycle with 26-32 cycle days.\n* Fully healthy and be able to follow the training program.\n\nExclusion Criteria:\n\n* Hormonal contraceptive users,\n* Users of regular medication\n* Chronic disease\n* Past or present neurological disorder\n* Recent musculoskeletal injury","35 Years",{"count":260,"type":20},111,[23],"The menstrual cycle implies a basic difference in the biology of women and men but the effect of the hormonal variation on training protocols and physical performance is still not fully understood. Despite no existing evidence, the advice to periodize exercise according to the menstrual cycle has been widely spread among elite athletes, coaches, and sports federations. The advice is based on underpowered studies with considerable methodological weaknesses regarding determination of cycle phase, inclusion of athletes and lack of adequate control groups.\n\nThe purpose of this randomized, controlled study is to evaluate the effect of exercise periodization on aerobic fitness during different phases of the menstrual cycle. Further, the effect will be related to premenstrual symptoms, body composition and skeletal muscle morphology, sex hormone receptors, metabolic enzymes, and markers of muscle protein synthesis. This study will be well controlled and follow methodology recommendations for menstrual cycle research in sports and exercise.\n\nFemale athletes of fertile age will be randomized to different training regimens during three menstrual cycles (12 weeks):\n\nGroup A: Training three times a week throughout the menstrual cycle. Group B: Follicular phase-based training five times a week during the follicular phase and thereafter once a week during the luteal phase.\n\nGroup C: Luteal phase-based training five times a week during the luteal phase and once a week in the follicular phase.\n\nThe exercise will consist of high intensity intermittent spinning classes. Assessment of aerobic fitness and power will be performed at baseline, and again after three completed menstrual cycles. On the same day, body composition will be examined by DXA and blood samples will be collected for analysis of hormones and binding proteins. To confirm menstrual cycle phase, blood samples will be collected for hormone determination, and urinary stick will be used for detection of ovulation. Subjective ratings of menstrual cycle related symptoms will be performed every day. In a subgroup of women, muscle biopsies will be collected from m vastus lateralis at baseline and at the end of the study. This study will contribute to improved knowledge about exercise periodization in relation to the menstrual cycle. Well-grounded data is crucial to give evidence-based recommendations to female athletes when planning their training protocol to optimize training results and performance.",[264,265,35,266],"Menstrual Cycle","Exercise","Athletic Performance",[264,265,35,266],"2025-08-27",{"date":270,"type":53},"2025-09-04",{"date":272,"type":53},"2023-08-01",{"date":274,"type":20},"2026-07",{"name":276,"class":60},"Karolinska Institutet",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":71,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":94},"100593790","sexual-health-of-sub-saharan-african-migrant-women-recently-diagnosed-with-hiv-in-le-de-france-missed-opportunities-for-prevention-100593790","NCT07011017","Sexual Health of Sub-Saharan African Migrant Women Recently Diagnosed With HIV in Île-de-France: Missed Opportunities for Prevention","Inclusion Criteria:\n\n* Sub-Saharan African migrant women recently diagnosed with HIV (from 2021 onward)\n* HIV diagnosis made on French territory\n* Aged 18 years or older\n\nExclusion Criteria:\n\n* Inability to inform the patient about the study due to a language barrier or other obstacle\n* HIV diagnosis made before 2021\n* HIV diagnosis made in the country of origin\n* Under 18 years of age",{"count":284,"type":20},45,"This study looks at the sexual health of women from Sub-Saharan Africa who recently found out they have HIV after arriving in Île-de-France. It aims to understand their risk factors and identify missed chances for HIV testing and prevention. The goal is to improve care and support for these women by learning more about their experiences and the challenges they face.",[287,30,288,35,289,290,291,292],"HIV Infections","Migrants","Health Services Accessibility","Sub-Saharan Africa","Risk-Taking","Vulnerable Populations","2025-05-30",{"date":295,"type":53},"2025-06-08",{"date":297,"type":20},"2025-06-15",{"date":299,"type":20},"2025-11-15",{"name":301,"class":60},"Centre Hospitalier de Saint-Denis",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":70,"sex":71,"minAge":309,"maxAge":258,"enrollmentInfo":310,"targetDuration":4,"studyType":21,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":215,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":4},"100500523","the-effect-of-continuous-midwife-support-on-various-parameters-related-to-pregnancy-childbirth-and-postpartum-period-100500523","NCT05797363","The Effect of Continuous Midwife Support on Various Parameters Related to Pregnancy, Childbirth and Postpartum Period","The Effect of Continuous Midwife Support During Pregnancy, Childbirth and Postpartum Processes Starting From Preconceptional Period on Various Parameters Related to Pregnancy, Delivery and Postpartum Period: A Randomized Controlled Study\"","Inclusion Criteria:\n\n* She's newly married.\n* Women without children.\n\nExclusion Criteria:\n\n* women's desire to stop working","19 Years",{"count":311,"type":20},150,[23],"There is a need for studies with a high level of evidence regarding the effect of supportive care given during the preconceptional period, pregnancy, childbirth and postpartum processes. With this planned study, it is aimed to evaluate the effect of continuous midwife support during pregnancy, birth and postpartum periods, starting from the preconceptional period, on various parameters related to pregnancy, birth and postpartum period. The research is planned as a randomized controlled experimental study. It consists of two groups, the study group and the control group. 75 women out of 150 women will form the control group and 75 women will form the study group. The women in the working group will be given individual training in line with their needs. Data will be collected by using the checklist and many scales used by the control and study groups in preconceptional counseling recommended by ACOG (American College of Obstetricians and Gynecologists).",[315,316,35],"Pregnant Women","Childbirth","2023-04-02",{"date":319,"type":53},"2023-04-04",{"date":321,"type":20},"2023-04-15",{"date":323,"type":20},"2027-12-30",{"name":325,"class":60},"Amasya University"]